Department of Surgery and Cancer, Imperial College London, London, UK.
What's known on the subject? and What does the study add? Recent studies have demonstrated the efficacy of various new treatments. These have been in diverse areas of therapeutics research, including immunology and targeted biological therapy, as well as in new ways of approaching hormone refractory disease. The present paper seeks to review all of the key advances that have been reported in late-stage clinical studies and place them into the context of managing patients with advanced prostate cancer.
To describe some of the most exciting late stage clinical developments in the field of new therapies for advanced prostate cancer.
Pubmed was searched for articles pertaining to prostate cancer therapeutics clinical trials in the last 3 years.
Key positive trials in the areas of androgen resistance, tumour immunology, molecularly targeted agents and cytotoxics were reviewed and discussed in the context of metastatic prostate cancer.
Treatments emerging from these areas of scientific endeavour are progressing into clinical trials and are both good cause for hope in patients, and excellent examples of mechanism based drug discovery.
Written by:
Alifrangis C, O'Hanlon-Brown C, Tuthill M, Waxman J. Are you the author?
Reference: BJU Int. 2011 Sep 20. Epub ahead of print.
doi: 10.1111/j.1464-410X.2011.10570.x
PubMed Abstract
PMID: 21933331
UroToday.com Prostate Cancer Section
